Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeAgeTrial IDs
Phase II, Phase ITissue collection/Repository, Treatment18 and overS0905
NCI-2011-02015, CDR0000665415, SWOG-S0905, NCT01064648

Trial Description

Summary

This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.

Further Study Information

OBJECTIVES:

I. To establish the maximum tolerated dose and the recommended phase II dose of cediranib maleate in combination with pemetrexed disodium and cisplatin in patients with malignant pleural mesothelioma. (Phase I)

II. To compare the progression-free survival of patients treated with pemetrexed disodium and cisplatin with vs without cediranib maleate. (Phase II)

III. To compare the overall survival of patients treated with these regimens. (Phase II)

IV. To assess the safety and toxicity profile of these regimens.

V. To assess the response rate (confirmed and unconfirmed, complete and partial responses) and disease control rate (responsive or stable disease) using RECIST criteria and modified RECIST criteria for pleural tumors in a subset of patients with measurable disease. (Phase II)

VI. To assess the rate of agreement between local and central pathology review of mesothelioma and its histologic subtypes. (Phase II)

VII. To collect specimens for banking for use in future research studies. (Phase II)

OUTLINE: This is a multicenter, phase I dose-escalation study of cediranib maleate followed by a phase II randomized study. Patients enrolled in the phase II portion of the study are stratified according to Zubrod performance status (0-1 vs 2) and histologic subtype (epithelioid vs biphasic/sarcomatoid).

PHASE I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive pemetrexed disodium IV over 10 minutes and cisplatin IV over 2 hours on day 1 and oral cediranib maleate once daily at the maximum tolerated dose determined in phase I on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral cediranib maleate alone once daily in the absence of disease progression or unacceptable toxicity.

ARM II: Patients receive pemetrexed disodium and cisplatin as in arm I and oral placebo once daily on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. Patients then receive oral placebo alone once daily in the absence of disease progression or unacceptable toxicity.

After completion of study therapy, patients are followed up periodically for up to 3 years.

Eligibility Criteria

Inclusion Criteria:

Histologically or cytologically confirmed malignant pleural mesothelioma

Not planning to undergo surgical resection

Zubrod performance status 0-2

Platelet count ≥ 100,000/mm^3

SGOT or SGPT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastases are present)

Proteinuria ≤ +1 on 2 consecutive dipsticks taken ≥ 7 days apart

Repeat urinalysis not required provided first urinalysis shows no protein

No mean QTc > 500 msec (with Bazett correction) by ECG or other significant ECG abnormality

No clinically significant hemoptysis, defined as > 1 tablespoon of bright red blood, within the past year

ANC ≥ 1,500/mm^3

No known HIV infection

No other malignancy within the past 5 years except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or adequately treated stage I or II cancer from which the patient is currently in complete remission.

Hemoglobin ≥ 9.0 g/dL (transfusion allowed)

Total bilirubin ≤ 1.5 times upper limit of normal (ULN)

Serum creatinine ≤ 1.5 times ULN

Creatinine clearance ≥ 60 mL/min

Not pregnant or nursing

Fertile patients must agree to use effective contraception

Must be able to swallow oral medications

No NYHA class III-IV congestive heart failure

No prior systemic therapy (chemotherapy or other biological therapy) for unresectable malignant pleural mesothelioma

Prior systemicchemotherapy or biologic therapy as neoadjuvant or adjuvant therapy allowed provided disease has recurred and systemic therapy was completed > 6 months before study entry

No prior therapy with any of the study drugs

At least 28 days since prior surgery (e.g., pleurectomy, pleurodeses, thoracic or other major surgeries) and recovered

At least 28 days since prior radiotherapy and recovered

No concurrent medication that may markedly affect renal function (e.g., vancomycin, amphotericin, pentamidine)

No concurrent drugs or biologics with proarrhythmic potential

No concurrent major surgery

No other concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy or any other type of therapy for treatment of cancer

Patients must have measurable or non-measurable disease by both RECIST and modified RECIST criteria for pleural tumors as documented by CT scan; examinations for assessment of measurable disease must have been completed within 28 days prior to registration; examinations for assessment of non-measurable disease must have been performed within 42 days prior to registration; all disease must be assessed and documented on the RECIST 1.1 and Modified RECIST Baseline Tumor Assessment Form

Trial Contact Information

Trial Lead Organizations / Sponsors / Collaborators

National Cancer Institute

  • National Cancer Institute
Anne S. Tsao, Principal Investigator

Trial Sites

U.S.A.

Arkansas
Rogers

Highlands Oncology Group-Rogers

Joseph Thaddeus Beck
Ph: 800-381-6939

Joseph Thaddeus Beck
Principal Investigator

California
Antioch

Kaiser Permanente-Deer Valley Medical Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Burbank

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

Fremont

Kaiser Permanente-Fremont

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Fresno

Kaiser Permanente

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Los Angeles

Los Angeles County-USC Medical Center

Barbara Jennifer Gitlitz
Ph: 323-865-0451

Barbara Jennifer Gitlitz
Principal Investigator

USC / Norris Comprehensive Cancer Center

Barbara Jennifer Gitlitz
Ph: 323-865-0451

Barbara Jennifer Gitlitz
Principal Investigator

Modesto

Kaiser Permanente-Modesto

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Oakland

Kaiser Permanente-Oakland

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Orange

UC Irvine Health/Chao Family Comprehensive Cancer Center

Sai-Hong Ignatius Ou
Ph: 877-827-8839
Email: ucstudy@uci.edu

Sai-Hong Ignatius Ou
Principal Investigator

Redwood City

Kaiser Permanente-Redwood City

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Richmond

Kaiser Permanente-Richmond

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Roseville

Kaiser Permanente-Roseville

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Sacramento

Kaiser Permanente - Sacramento

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Kaiser Permanente-South Sacramento

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

University of California Davis Comprehensive Cancer Center

Karen L. Kelly
Ph: 916-734-3089

Karen L. Kelly
Principal Investigator

San Francisco

Kaiser Permanente-San Francisco

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

San Jose

Kaiser Permanente-Santa Teresa-San Jose

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

San Leandro

Kaiser Permanente San Leandro

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

San Rafael

Kaiser Permanente-San Rafael

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Santa Clara

Kaiser Permanente Medical Center - Santa Clara

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Santa Rosa

Kaiser Permanente-Santa Rosa

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

South San Francisco

Kaiser Permanente-South San Francisco

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Stockton

Kaiser Permanente-Stockton

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Vacaville

Kaiser Permanente Medical Center-Vacaville

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Vallejo

Kaiser Permanente-Vallejo

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Walnut Creek

Kaiser Permanente-Walnut Creek

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Connecticut
Hartford

Saint Francis Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Hawaii
Honolulu

Kaiser Permanente Moanalua Medical Center

Louis Fehrenbacher
Ph: 626-564-3455

Louis Fehrenbacher
Principal Investigator

Idaho
Boise

Saint Alphonsus Cancer Care Center-Boise

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Coeur D'Alene

Kootenai Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Post Falls

Kootenai Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Sandpoint

Kootenai Cancer

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Illinois
Bloomington

Illinois CancerCare-Bloomington

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Joseph Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Canton

Illinois CancerCare-Canton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carbondale

Memorial Hospital of Carbondale

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Carthage

Illinois CancerCare-Carthage

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Centralia

Centralia Oncology Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Decatur

Cancer Care Center of Decatur

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Central Illinois CCOP

Anne S. Tsao
Ph: 713-792-6363

Anne S. Tsao
Principal Investigator

Decatur Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Effingham

Crossroads Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Eureka

Illinois CancerCare-Eureka

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Galesburg

Illinois CancerCare Galesburg

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Western Illinois Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Kewanee

Illinois CancerCare-Kewanee Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Macomb

Illinois CancerCare-Macomb

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Ottawa

Illinois CancerCare-Ottawa Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Radiation Oncology of Northern Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin

Illinois CancerCare-Pekin

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Pekin Cancer Treatment Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peoria

Illinois CancerCare-Peoria

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Methodist Medical Center of Illinois

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

OSF Saint Francis Medical Center Radiation Oncology Service at the Central Illinois Comprehensive CC

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Peru

Illinois CancerCare-Peru

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Valley Radiation Oncology

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Princeton

Illinois CancerCare-Princeton

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield

Central Illinois Hematology Oncology Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Memorial Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southern Illinois University School of Medicine

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Springfield Clinic

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Swansea

Cancer Care Specialists of Illinois-Swansea

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Michigan
Ann Arbor

Saint Joseph Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

University of Michigan Comprehensive Cancer Center

Anne S. Tsao
Ph: 713-792-6363

Anne S. Tsao
Principal Investigator

Dearborn

Oakwood Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Detroit

Henry Ford Hospital

Robert Anthony Chapman
Ph: 313-916-1784

Robert Anthony Chapman
Principal Investigator

Saint John Hospital and Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Wayne State University/Karmanos Cancer Institute

Shirish M. Gadgeel
Ph: 313-576-9363

Shirish M. Gadgeel
Principal Investigator

Farmington Hills

Weisberg Cancer Treatment Center

Shirish M. Gadgeel
Ph: 313-576-9363

Shirish M. Gadgeel
Principal Investigator

Flint

Genesys Hurley Cancer Institute

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Hurley Medical Center

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Jackson

Allegiance Health

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Lansing

Sparrow Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Livonia

Saint Mary Mercy Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Pontiac

Saint Joseph Mercy Oakland

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Port Huron

Saint Joseph Mercy Port Huron

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Saginaw

Saint Mary's of Michigan

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Warren

Saint John Macomb-Oakland Hospital

Philip J. Stella
Ph: 734-712-4673

Philip J. Stella
Principal Investigator

Mississippi
Pascagoula

Singing River Hospital

James E. Clarkson
Ph: 228-809-5292

James E. Clarkson
Principal Investigator

Missouri
Bonne Terre

Parkland Health Center-Bonne Terre

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Cape Girardeau

Saint Francis Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Southeast Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Jefferson City

Capital Region Medical Center-Goldschmidt Cancer Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Saint Louis

Missouri Baptist Medical Center

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sainte Genevieve

Sainte Genevieve County Memorial Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sullivan

Missouri Baptist Sullivan Hospital

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Sunset Hills

Missouri Baptist Outpatient Center-Sunset Hills

James Lloyd Wade
Ph: 217-876-4740
Email: kcheek@dmhhs.org

James Lloyd Wade
Principal Investigator

Montana
Billings

Billings Clinic Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Montana Cancer Consortium CCOP

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Vincent Healthcare

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Bozeman

Bozeman Deaconess Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Butte

Saint James Community Hospital and Cancer Treatment Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Great Falls

Benefis Healthcare- Sletten Cancer Institute

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Helena

Saint Peter's Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Kalispell

Kalispell Regional Medical Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Missoula

Community Medical Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Saint Patrick Hospital - Community Hospital

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

North Carolina
Charlotte

Carolina Surgical Clinic of Charlotte PA

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Novant Health Presbyterian Medical Center

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Oncology Specialists of Charlotte

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Southern Oncology Specialists-Charlotte

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Hendersonville

Hendersonville Hematology and Oncology at Pardee

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Margaret R Pardee Memorial Hospital

James Earl Radford
Ph: 828-696-4716

James Earl Radford
Principal Investigator

Huntersville

Lake Norman Hematology Oncology Specialists-Huntersville

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Southern Oncology Specialists-Huntersville

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Matthews

Matthews Radiation Oncology Center

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Novant Health Cancer Specialists-Matthews

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Mooresville

Lake Norman Hematology Oncology Specialists-Mooresville

Justin Peter Favaro
Ph: 704-384-5369

Justin Peter Favaro
Principal Investigator

Statesville

Iredell Memorial Hospital

Ruby Ann Grimm
Ph: 704-873-5661

Ruby Ann Grimm
Principal Investigator

Winston-Salem

Southeast Cancer Control Consortium CCOP

Anne S. Tsao
Ph: 713-792-6363

Anne S. Tsao
Principal Investigator

Ohio
Belpre

Strecker Cancer Center-Belpre

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Chillicothe

Adena Regional Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Columbus

Columbus Oncology and Hematology Associates Inc

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Doctors Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grant Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Mount Carmel Health Center West

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Riverside Methodist Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

The Mark H Zangmeister Center

John Philip Kuebler
Ph: 800-446-5532

John Philip Kuebler
Principal Investigator

Delaware

Delaware Health Center-Grady Cancer Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Delaware Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Grady Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Lancaster

Fairfield Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Marietta

Marietta Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Marion

OneHealth Marion General Hospital

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Mount Vernon

Knox Community Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Newark

Licking Memorial Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Newark Radiation Oncology

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Portsmouth

Southern Ohio Medical Center

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Springfield

Springfield Regional Medical Center

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Westerville

Saint Ann's Hospital

John Philip Kuebler
Ph: 614-566-3275

John Philip Kuebler
Principal Investigator

Zanesville

Genesis HealthCare System

John Philip Kuebler
Ph: 614-488-2745
Email: sheree@columbusccop.org

John Philip Kuebler
Principal Investigator

Oregon
Portland

Providence Portland Medical Center

Keith S. Lanier
Ph: 503-215-6412

Keith S. Lanier
Principal Investigator

SWOG

Anne S. Tsao
Email: astsao@mdanderson.org

Anne S. Tsao
Principal Investigator

South Carolina
Easley

Greenville Health System Cancer Institute-Easley

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville

Greenville Health System Cancer Institute-Andrews

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Butternut

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Eastside

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Health System Cancer Institute-Faris

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greenville Memorial Hospital

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Greer

Greenville Health System Cancer Institute-Greer

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Seneca

Greenville Health System Cancer Institute-Seneca

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Spartanburg

Greenville Health System Cancer Institute-Spartanburg

Jeffrey K. Giguere
Ph: 864-241-6251

Jeffrey K. Giguere
Principal Investigator

Tennessee
Kingsport

Wellmont Holston Valley Hospital and Medical Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Wellmont Medical Associates Oncology and Hematology-Kingsport

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Texas
Houston

M D Anderson Cancer Center

Anne S. Tsao
Ph: 713-792-3245

Anne S. Tsao
Principal Investigator

San Antonio

Southwest Oncology Group (SWOG) Research Base

Anne S. Tsao
Email: astsao@mdanderson.org

Anne S. Tsao
Principal Investigator

Virginia
Danville

Danville Hematology Oncology

Qiwei William Gai
Ph: 434-793-0044

Qiwei William Gai
Principal Investigator

Danville Regional Medical Center

Qiwei William Gai
Ph: 434-793-0044

Qiwei William Gai
Principal Investigator

Norton

Southwest VA Regional Cancer Center

Asheesh Shipstone
Ph: 423-578-8538

Asheesh Shipstone
Principal Investigator

Washington
Anacortes

Cancer Care Center at Island Hospital

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Bellingham

PeaceHealth Saint Joseph Medical Center

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Bremerton

Harrison HealthPartners Hematology and Oncology-Bremerton

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Burien

Highline Medical Center-Main Campus

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Edmonds

Swedish Medical Center-Edmonds

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Issaquah

Swedish Cancer Institute-Issaquah

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Poulsbo

Harrison HealthPartners Hematology and Oncology-Poulsbo

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Seattle

Group Health Cooperative-Seattle

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Minor and James Medical PLLC

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Swedish Medical Center-Ballard Campus

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Swedish Medical Center-First Hill

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Spokane

Evergreen Hematology and Oncology PS

Gary E. Goodman
Ph: 206-386-2323
Email: patra.grevstad@swedish.org

Gary E. Goodman
Principal Investigator

Wyoming
Cody

Big Horn Basin Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Billings Clinic-Cody

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Sheridan

Welch Cancer Center

Benjamin T. Marchello
Ph: 800-648-6274

Benjamin T. Marchello
Principal Investigator

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01064648

Note: Information about participating sites on pharmaceutical industry trials may be incomplete. Please visit the ClinicalTrials.gov record via the link above for more information about participating sites.